ArticleJournal of the Canadian Association of Gastroenterology2021
Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results.
Article in Journal of the Canadian Association of Gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.BMJ open gastroenterology · 2021Trial
- Multidisciplinary Delphi consensus statement on minimal standards for clinical metadata and end points in microbiome studies.Nature reviews. Gastroenterology & hepatology · 2026Review
- Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort.Crohn's & colitis 360 · 2026Article
- Advancing IBD Management: A Literature Review on the Role of Non-Invasive Blood-Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment.Clinical and translational science · 2026Review
- Article
- Recent Trend of Laboratory Tests in Common Gastrointestinal Tract Disorders.Diagnostics (Basel, Switzerland) · 2025Review
- The Molecular Landscape of Inflammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.Biomedicines · 2025Review
- Diagnostic Potential of Periostin, Galectin-3 and Tenascin C Serum Measurements in Inflammatory Bowel Disease: Pilot Study.International journal of molecular sciences · 2025Article
- Urinary prostaglandin metabolites evaluation for activity monitoring in inflammatory bowel disease.Scientific reports · 2025Article
- Comparison between fecal calprotectin and magnetic resonance enterography in ileal Crohn's disease for activity disease assessment: a systematic review.Translational gastroenterology and hepatology · 2025Review
- Serum calprotectin correlates with severity of severe fever with thrombocytopenia syndrome.Frontiers in microbiology · 2025Article
- Neutrophil Extracellular Traps in Pediatric Inflammatory Bowel Disease: A Potential Role in Ulcerative Colitis.International journal of molecular sciences · 2024Article
- Effects of fecal microbiota transplantation for recurrent Clostridium difficile infection in children on kidney replacement therapy: a pilot study.Pediatric nephrology (Berlin, Germany) · 2024Article
- Biomarkers That Predict Crohn's Disease Outcomes.Journal of the Canadian Association of Gastroenterology · 2024Review
- Fatigue in Patients with Newly Diagnosed Inflammatory Bowel Disease: Results from a Prospective Inception Cohort, the IBSEN III Study.Journal of Crohn's & colitis · 2023Article
- Symptoms and symptom clusters in patients newly diagnosed with inflammatory bowel disease: results from the IBSEN III Study.BMC gastroenterology · 2023Article
- A novel inflammatory marker for extensive ulcerative colitis; Endocan.BMC gastroenterology · 2023Article
- Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis.Therapeutic advances in gastroenterology · 2023Review
- Reliability of C-reactive protein as an inflammatory marker in patients with immune-mediated inflammatory diseases and liver dysfunction.Rheumatology advances in practice · 2023Article
- Concurrent functional gastrointestinal disorders in patients with inflammatory bowel disease.Frontiers in gastroenterology (Lausanne, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to compare fecal calprotectin (FC) levels with other commonly used parameters as part of patient care during evaluation for inflammatory bowel disease (IBD).
methodsWe recruited adult IBD patients with ulcerative colitis (UC) and Crohn's disease (CD) and compared the results of the patient's biopsy results (i.e., inflamed versus noninflamed) for six sites (i.e., ileum, ascending colon, transverse colon, descending colon, sigmoid colon, rectum) with concentrations of C-reactive protein (CRP), total leucocytes and fecal calprotectin (FC).
resultsWe found that FC was significantly elevated in a concentration-dependent manner that correlated with the number of active inflammation sites reported in biopsy. Although CRP and leucocyte measurements trended upwards in line with inflammation reported from biopsy, the results were highly variable and highlighted poor reliability of these biomarkers for indicating IBD inflammation.
conclusionsThese results strongly suggest that FC correlates best with biopsy reports and is a superior marker than CRP and leucocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.